Status: Recruiting
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.
Participants needed: 44
Trial details
Phase: Phase 1Age: 16-80Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 16, 2026Locations: 1
Eligibility criteria
Patients with all cancer histology, with an HLA-A*02:01, HLA-A*02:05 or HLA-A*02... [+21]
Presence of clinically significant ≥ Grade 2 toxicity from previous anticancer t... [+24]